| Literature DB >> 25446228 |
Nilam Patel1, Christian Grillon2, Nevia Pavletic2, Dana Rosen2, Daniel S Pine2, Monique Ernst3.
Abstract
The modulation of risk-taking is critical for adaptive and optimal behavior. This study examined how oxytocin (OT) and arginine vasopressin (AVP) influence risk-taking in function of three parameters: sex, risk-valence, and social context. Twenty-nine healthy adults (14 males) completed a risk-taking task, the Stunt task, both in a social-stress (evaluation by unfamiliar peers) and non-social context, in three separate drug treatment sessions. During each session, one of three drugs, OT, AVP, or placebo (PLC), was administered intra-nasally. OT and AVP relative to PLC reduced betting-rate (risk-averse effect). This risk-averse effect was further qualified: AVP reduced risk-taking in the positive risk-valence (high win-probability), and regardless of social context or sex. In contrast, OT reduced risk-taking in the negative risk-valence (low win-probability), and only in the social-stress context and men. The reduction in risk-taking might serve a role in defensive behavior. These findings extend the role of these neuromodulators to behaviors beyond the social realm. How the behavioral modulation of risk-taking maps onto the function of the neural targets of OT and AVP may be the next step in this line of research. Published by Elsevier Inc.Entities:
Keywords: Motivated behavior; Neuropeptides; Risk-valence; Sex; Social stress
Mesh:
Substances:
Year: 2014 PMID: 25446228 PMCID: PMC4274653 DOI: 10.1016/j.physbeh.2014.11.018
Source DB: PubMed Journal: Physiol Behav ISSN: 0031-9384